<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HB6B1145C005D4D9DAB6067F7B647AA65" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 4472 IH: US–Israel Global Neuroscience Partnership Act of 2014</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-04-10</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4472</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140410">April 10, 2014</action-date>
			<action-desc><sponsor name-id="F000043">Mr. Fattah</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To provide for the establishment of a grant program to support United States-Israeli cooperation
			 for neuroscience-related research, and for other purposes.</official-title>
	</form>
	<legis-body id="H67C7AEE6257F42A1B2611BB45E5CED01" style="OLC">
		<section id="H86E94980FE4647A38F47C357A739568E" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>US–Israel Global Neuroscience Partnership Act of 2014</short-title></quote>.</text>
		</section><section id="HD92ED7FD4FF54A3CBBA5EC33CE923F00"><enum>2.</enum><header>Findings</header>
			<text display-inline="no-display-inline">Congress finds that—</text>
			<paragraph id="H915FA4D9636B436B90CBB83E5BFA2889"><enum>(1)</enum><text display-inline="yes-display-inline">it is in the highest national security interests of the United States to develop
			 neuroscience-related research and neurotechnology;</text>
			</paragraph><paragraph id="H6D50DD6D40B7409B94FC8860353B050C"><enum>(2)</enum><text>the State of Israel is a steadfast ally of the United States;</text>
			</paragraph><paragraph id="H49C1D21D469F4C0EB32BBF2782BDBAA6"><enum>(3)</enum><text>the special relationship between the United States and Israel is manifested in a variety of
			 cooperative scientific research and development programs, such as—</text>
				<subparagraph id="HF6FA10AD3C6D4C5681ABA602DE534809"><enum>(A)</enum><text>the United States-Israel Binational Science Foundation; and</text>
				</subparagraph><subparagraph id="HA9C27B1E2F2C4FAE8AD9C8CD71A4577B"><enum>(B)</enum><text>the United States-Israel Binational Industrial Research and Development Foundation;</text>
				</subparagraph></paragraph><paragraph id="H33727A3C9BAF4550B9CEDA669936001E"><enum>(4)</enum><text>those programs have made possible many scientific, technological, and commercial breakthroughs in
			 the fields of life sciences, medicine, bioengineering, agriculture,
			 biotechnology, communications, and others;</text>
			</paragraph><paragraph id="H7A41F8AA92134C3DBAF09CEBCC35DBCF"><enum>(5)</enum><text display-inline="yes-display-inline">in December 2011 the Office of Science and Technology Policy was directed by Congress to establish
			 an Interagency Working Group on Neuroscience which was chartered on June
			 20, 2012, is housed at the White House, and is currently convening
			 representatives across the Federal Government to make recommendations
			 about the future of neuroscience research;</text>
			</paragraph><paragraph id="H5631BAFD10F84A7BBBBDE91DF6654830"><enum>(6)</enum><text>Israeli scientists and engineers are at the forefront of research and development in the field of
			 neuroscience;</text>
			</paragraph><paragraph id="H58BEF4461C084534A397D79D8DA045D9"><enum>(7)</enum><text display-inline="yes-display-inline">Israel Brain Technologies is a nonprofit organization whose mission is to turn Israel into a global
			 brain technology and research leader by—</text>
				<subparagraph id="HC7A210CB12CE453F8EA7BFE9D06C44A8"><enum>(A)</enum><text>supporting applied brain research;</text>
				</subparagraph><subparagraph id="H5A0AF2264A8C435FA2FDE2233073C38F"><enum>(B)</enum><text>accelerating brain technology development;</text>
				</subparagraph><subparagraph id="HE86E5E0B3725462093AF36B9E9F0C9D1"><enum>(C)</enum><text>creating and fostering a community around neurotechnology; and</text>
				</subparagraph><subparagraph id="H5951565ABA1142D193A307A1D588FEBE"><enum>(D)</enum><text>attracting key stakeholders to partner and support brain technology in Israel; and</text>
				</subparagraph></paragraph><paragraph id="HA9A794BA0A404CDC86C2B4CA965705A0"><enum>(8)</enum><text>enhanced cooperation between the United States and Israel for the purpose of research and
			 development of neuroscience would be in the national interests of both
			 countries.</text>
			</paragraph></section><section id="HD568962BEFDD458885168CF6C4AF9523"><enum>3.</enum><header>Grants for neuroscience-related research</header>
			<subsection id="H4C8D936E156E46C6A0425F817DC8E2F6"><enum>(a)</enum><header>Authority</header><text>The Secretary, acting through the Director of the National Institutes of Health, in consultation
			 with the BIRD or BSF, shall award grants to eligible entities for
			 neuroscience-related research.</text>
			</subsection><subsection id="H9963240852A443BDB2ECC287A3BE45D4"><enum>(b)</enum><header>Application</header>
				<paragraph id="HAE44A155D46F41C4951BC7ED9FC82D2E"><enum>(1)</enum><header>Submission of applications</header><text>To receive a grant under this section, an eligible entity shall submit an application to the
			 Secretary containing such information and assurances as the Secretary, in
			 consultation with the BIRD or BSF, may require.</text>
				</paragraph><paragraph id="H49F66A9922CF43CD95CBAC1FFD2312AD"><enum>(2)</enum><header>Selection of eligible entities</header><text>The Secretary, in consultation with the Directors of the BIRD and BSF, may review any application
			 submitted by any eligible entity and select any eligible entity meeting
			 criteria established by the Secretary, in consultation with the Advisory
			 Board, for a grant under this section.</text>
				</paragraph></subsection><subsection id="H3F4486B42A6C472F9A3D5526D062E5CC"><enum>(c)</enum><header>Amount of grant</header><text>The amount of each grant awarded for a fiscal year under this section shall be determined by the
			 Secretary, in consultation with the BIRD or BSF.</text>
			</subsection><subsection id="HA07C087CF9AA4839B8E2C89585456D7B"><enum>(d)</enum><header>Recoupment</header>
				<paragraph id="HE8E133A75A524589BD86AA5CBAB69E93"><enum>(1)</enum><header>In general</header><text>Not later than 180 days after the date of enactment of this Act, the Secretary shall establish
			 procedures and criteria for recoupment in connection with any eligible
			 project carried out by an eligible entity that receives a grant under this
			 section, which has led to the development of a product or process which is
			 marketed or used.</text>
				</paragraph><paragraph id="H0F8D8D9FD5184C2D9E6FEBE6DA38FB22"><enum>(2)</enum><header>Amount required</header>
					<subparagraph id="H56B539EE70974DAD8FF5AC2EEB3A6C10"><enum>(A)</enum><text>Except as provided in subparagraph (B), such recoupment shall be required as a condition for award
			 and be proportional to the Federal share of the costs of such project, and
			 shall be derived from the proceeds of royalties or licensing fees received
			 in connection with such product or process.</text>
					</subparagraph><subparagraph id="H31EF85C4D19F4C5586C5D9C20E85BB8D"><enum>(B)</enum><text>In the case where a product or process is used by the recipient of a grant under this section for
			 the production and sale of its own products or processes, the recoupment
			 shall consist of a payment equivalent to the payment which would be made
			 under subparagraph (A).</text>
					</subparagraph></paragraph><paragraph id="H20EB7BC52B8445069E8AF76E1D7072AC"><enum>(3)</enum><header>Waiver</header><text>The Secretary may at any time waive or defer all or some of the recoupment requirements of this
			 subsection as necessary, depending on—</text>
					<subparagraph id="HD6FDA15EFA4B414FBC528090DE7AE6D4"><enum>(A)</enum><text>the commercial competitiveness of the entity or entities developing or using the product or
			 process;</text>
					</subparagraph><subparagraph id="HCC0685733A254C2F8622DE3636D921DA"><enum>(B)</enum><text>the profitability of the project; and</text>
					</subparagraph><subparagraph id="H1801A0DC7AAC4E33B6DB32CBE0CF0B45"><enum>(C)</enum><text>the commercial viability of the product or process utilized.</text>
					</subparagraph></paragraph></subsection><subsection id="HF49E8F6E556A444495CFB9E38992AE3F"><enum>(e)</enum><header>Private funds</header><text>The Secretary may accept contributions of funds from private sources to carry out this Act.</text>
			</subsection><subsection id="HA3B4D3C2B4A549B1B968A3E0CE067E0A"><enum>(f)</enum><header>Report</header><text>Not later than 180 days after receiving a grant under this section, each recipient shall submit a
			 report to the Secretary—</text>
				<paragraph id="H26BA9A542EB646C3AF9135EF7065CE0A"><enum>(1)</enum><text>documenting how the recipient used the grant funds; and</text>
				</paragraph><paragraph id="H517247A9C00446109E1E34C08F429D5A"><enum>(2)</enum><text>evaluating the level of success of each project funded by the grant.</text>
				</paragraph></subsection></section><section id="H68FB88D2956F4517BAC4124291C16BC6"><enum>4.</enum><header>International Neuroscience-Related Research Advisory Board</header>
			<subsection id="HA623B34B571E4FC8BB17904E849EE23C"><enum>(a)</enum><header>Establishment</header><text>There is established in the National Institutes of Health an International Neuroscience-Related
			 Research Advisory Board.</text>
			</subsection><subsection id="HE99B3633C26B497DA24DEA75697F3734"><enum>(b)</enum><header>Duties</header><text>The Advisory Board shall advise the Secretary on—</text>
				<paragraph id="H7C9F3A8A9F8A4C458E8063CB9B90789F"><enum>(1)</enum><text>criteria for the recipients of grants awarded under section 3(a);</text>
				</paragraph><paragraph id="H70FE0ABB949E4272AB991F8A0D7B93E7"><enum>(2)</enum><text>the total amount of grant money to be awarded to all grantees selected by the Secretary, in
			 consultation with the BIRD; and</text>
				</paragraph><paragraph id="HD871EFE903FD463DB287FA3A58217248"><enum>(3)</enum><text>the total amount of grant money to be awarded to all grantees selected by the Secretary, in
			 consultation with the BSF, for each fiscal year.</text>
				</paragraph></subsection><subsection id="H36D36548C3774187AD3D06E4AFFBF305"><enum>(c)</enum><header>Membership</header>
				<paragraph id="HBBE7CF0978C3435E910CFD83B307BACE"><enum>(1)</enum><header>Composition</header><text>The Advisory Board shall be composed of—</text>
					<subparagraph id="H458BE2C887D7482F856559976FB8B488"><enum>(A)</enum><text>1 member appointed by the Director of the National Science Foundation;</text>
					</subparagraph><subparagraph id="H9569B99C2BEB4F23BF24E76854CFAEAA"><enum>(B)</enum><text>1 member appointed by the Director of the National Institutes of Health;</text>
					</subparagraph><subparagraph id="H3DAE76C891AA4C1A9EBDEDFB40137011"><enum>(C)</enum><text>1 member appointed by the Director of the National Institute of Standards and Technology; and</text>
					</subparagraph><subparagraph id="H906E0377403242D391E9582BF01CCCE6"><enum>(D)</enum><text>in addition to the member appointed under subparagraph (B), 3 members who shall be Israeli
			 citizens, appointed by the Director of the National Institutes of Health
			 after consultation with appropriate officials in the Israeli Government.</text>
					</subparagraph></paragraph><paragraph id="H1CCB258DCEFF4CCA8141E8839974BDBC"><enum>(2)</enum><header>Deadline for appointments</header><text>The initial appointments under paragraph (1) shall be made not later than 60 days after the date of
			 enactment of this Act.</text>
				</paragraph><paragraph id="H74B372747A99485DABD6AEA36100DA8F"><enum>(3)</enum><header>Term</header><text>Each member of the Advisory Board shall be appointed for a term of 4 years.</text>
				</paragraph><paragraph id="H8CA49F8617424D338D1DA43904BB010B"><enum>(4)</enum><header>Vacancies</header><text>A vacancy on the Advisory Board shall be filled in the manner in which the original appointment was
			 made.</text>
				</paragraph><paragraph id="H4E2F2FC4299D4E58A2DE63B318ADEB31"><enum>(5)</enum><header>Basic pay</header>
					<subparagraph id="H7C660E0F421B40E4B28EF08A8A7D1F0C"><enum>(A)</enum><header>Compensation</header><text>A member of the Advisory Board shall serve without pay.</text>
					</subparagraph><subparagraph id="HCECEF265A54B49BEA79F4B775F40D43A"><enum>(B)</enum><header>Travel expenses</header><text>Each member of the Advisory Board shall receive travel expenses, including per diem in lieu of
			 subsistence, in accordance with applicable provisions of subchapter I of
			 <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/57">chapter 57</external-xref> of title 5, United States Code.</text>
					</subparagraph></paragraph><paragraph id="HAA2C5DF4B2C947D5814603909286493E"><enum>(6)</enum><header>Quorum</header><text>Three members of the Advisory Board shall constitute a quorum.</text>
				</paragraph><paragraph id="H50E95F8D9C92444E935E0F11BF3B326D"><enum>(7)</enum><header>Chairperson</header><text>The Chairperson of the Advisory Board shall be designated by the Director of the National
			 Institutes of Health from among the members appointed by the Director at
			 the time of the appointment.</text>
				</paragraph><paragraph id="H888071A7109D4698A515F2B49E781D37"><enum>(8)</enum><header>Meetings</header><text>The Advisory Board shall meet at least once annually at the call of the Chairperson.</text>
				</paragraph></subsection><subsection id="HD76AAF1751904F648BF46A45D899F0C5"><enum>(d)</enum><header>Termination</header><text>Section 14(a)(2)(B) of the Federal Advisory Committee Act (5 U.S.C. App.) shall not apply to the
			 Advisory Board.</text>
			</subsection></section><section id="H77E3660E9C194896A196020914FA41A7"><enum>5.</enum><header>Definitions</header><text display-inline="no-display-inline">In this Act:</text>
			<paragraph id="H6263CCD6E83E499DAC72F464F1AC2453"><enum>(1)</enum><header>Advisory board</header><text>The term <term>Advisory Board</term> means the International Neuroscience-Related Research Advisory Board established by section 4(a).</text>
			</paragraph><paragraph id="H3385FD41481B42EEB63C083251D5B209"><enum>(2)</enum><header>BIRD</header><text>The term <term>BIRD</term> means the Israel-United States Binational Industrial Research and Development Foundation.</text>
			</paragraph><paragraph id="HD83C4F51C6664FE9BB651B68EEF68986"><enum>(3)</enum><header>BSF</header><text>The term <term>BSF</term> means the United States-Israel Binational Science Foundation.</text>
			</paragraph><paragraph id="H2BCB7DF0AF9A430F839C4FD148AB1A69"><enum>(4)</enum><header>Eligible entity</header><text>The term <term>eligible entity</term> means a joint venture comprised of both Israeli and United States private business entities or a
			 joint venture comprised of both Israeli academic persons (who reside and
			 work in Israel) and United States academic persons, that—</text>
				<subparagraph id="H8BAB0A38B1E5486FA803885B854AAF5E"><enum>(A)</enum><text>carries out an eligible project; and</text>
				</subparagraph><subparagraph id="H8C58060F116D452D93F7C23088ED929C"><enum>(B)</enum><text>is selected by the Secretary, in consultation with the BIRD or BSF, using the criteria established
			 by the Secretary, in consultation with the Advisory Board.</text>
				</subparagraph></paragraph><paragraph id="HEB602DD2ACB448CEA6C08E5AA9373F80"><enum>(5)</enum><header>Eligible project</header><text>The term <term>eligible project</term> means a project to encourage cooperation between the United States and Israel on
			 neuroscience-related research.</text>
			</paragraph><paragraph id="HF2174EF86D4C45E0B09A31B131845EA2"><enum>(6)</enum><header>Secretary</header><text>The term <term>Secretary</term> means the Secretary of Health and Human Services.</text>
			</paragraph></section><section id="H26E10CE31AE74A3EBCFD191C64125211"><enum>6.</enum><header>Termination</header><text display-inline="no-display-inline">The grant program authorized under section 3 and the Advisory Board shall terminate upon the
			 expiration of the 7-year period which begins on the date of the enactment
			 of this Act.</text>
		</section><section id="HE3154DF1929E45A38A851728CEF22C4B"><enum>7.</enum><header>Authorization of appropriations</header><text display-inline="no-display-inline">The Secretary is authorized to expend not more than $20,000,000 to carry out this Act for each of
			 fiscal years 2014 through 2020.</text>
		</section></legis-body>
</bill>


